Intranasal Vaccination with rePcrV Protects against Pseudomonas aeruginosa and Generates Lung Tissue-Resident Memory T Cells. (26th November 2022)

• Record Type: Journal Article
• Authors: Ou, Yangxue; Wang, Ying; Yu, Ting; Cui, Zhiyuan; Chen, Xin; Zhang, Weijun; Zou, Quanming; Gu, Jiang; Zuo, Qianfei
• Other Names: Zhu Lele Academic Editor.
• Is Part Of: Journal of immunology research. Volume 2022(2022)
• Publication Date: 2022-11-26
• Subjects: Immunology -- Periodicals; Immunology -- Research -- Periodicals; 616.07905
• DOI: 10.1155/2022/1403788
• Languages: English
• ISSNs: 2314-8861

Abstract

Abstract : Tissue-resident memory T (TRM ) cells are immune sentinels that bear a key role in the local immune system and rapidly respond to infection. Our previous studies showed that mucosal immunization via intranasal pathways was more effective than intramuscular route. However, the mechanism of enhanced protective immunity remains unclear. Here, we formulated a Pseudomonas aeruginosa vaccine composed of type III secretion protein PcrV from P. aeruginosa and curdlan adjuvant and then administered by the intranasal route. Flow cytometry and immunofluorescence staining showed that the ratio of CD44 + CD62L - CD69 + CD4 + TRM cells induced by this vaccine was significantly increased, and IL-17A production was notably enhanced. Further analysis revealed that vaccinated mice can protect against the P. aeruginosa challenge even after administration with FTY720 treatment. What is more, our results showed that CD4 + TRM might be involved in the recruitment of neutrophils and provided partial protection against Pseudomonas aeruginosa . Taken together, these data demonstrated that CD4 + TRM cells were elicited in lung tissues after immunization with rePcrV and contributed to protective immunity. Furthermore, it provided novel strategies for the development of vaccines for P. aeruginosa and other respiratory-targeted vaccines.